Discontinuation of Therapy
Links shared publicly online about this topic
Analyzing Disease Flares: Impact of Discontinuing Targeted Therapy Unclear
onclive.com — “It is always difficult to distinguish what may legitimately be considered disease flare from the more likely scenario of the events simply representing the natural history of the malignancy.” View full resource at onclive.com
Most Recently Shared on March 21, 2012 at 1:56 pm By:
Analyzing Disease Flares: Impact of Discontinuing Targeted Therapy Unclear http://t.co/aGVquZN2
Discontinuation Of Root Canal Therapy And Proceeding With Crown | identalhub.com
identalhub.com — “Discontinuation Of Root Canal Therapy And Proceeding With Crown | identalhub.com” View full resource at identalhub.com
Most Recently Shared on August 28, 2011 at 2:11 am By:
Dr. Steven Goldy Doctor and Dentist
Discontinuation Of Root Canal Therapy And Proceeding With Crown ... http://t.co/4BuC3l1
Ipsen Announces Discontinuation Of The Development Of Irosustat In Monotherapy
medicalnewstoday.com — “Ipsen (Paris:IPN) (Euronext: IPN - ADR: IPSEY) today announced its decision to assess the alternative development of Irosustat (BN 83495) in combination with other hormonal therapies. This decisio” View full resource at medicalnewstoday.com
Most Recently Shared on June 6, 2011 at 4:05 pm By:
MNT Women's Health Health News
Ipsen Announces Discontinuation Of The Development Of Irosustat In Monotherapy http://mnt.to/3WP3 #womenshealth
SDI Reports: Approximately Half Of Patients Prescribed The Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months
medicalnewstoday.com — “According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment wi” View full resource at medicalnewstoday.com
Most Recently Shared on June 16, 2010 at 1:07 pm By:
MNT Bones/Orthopedic Health News
SDI Reports: Approximately Half Of Patients Prescribed The Most Popular Osteoporosis Drugs Discontinue Therapy Within ... http://mnt.to/3DVz
APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued
medicalnewstoday.com — “Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syn” View full resource at medicalnewstoday.com
Most Recently Shared on November 20, 2010 at 3:05 am By:
APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued http://mnt.to/3MTp #heart #heartdisease
Arquivos Brasileiros de Endocrinologia & Metabologia - The effects of discontinuing long term alendronate therapy in a clinical practice setting
scielo.br — “Arquivos Brasileiros de Endocrinologia & Metabologia - The effects of discontinuing long term alendronate therapy in a clinical practice setting” View full resource at scielo.br
Most Recently Shared on July 17, 2011 at 12:52 pm By:
The effects of discontinuing long term alendronate therapy in a clinical practice setting: CONCLUSION: Observed ... http://bit.ly/p2Sbsq
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents | Cardiology
touchcardiology.com — “To emphasize the potential complications of premature discontinuation of thienopyridine therapy and address potential strategies to minimize this occurrence. INTENDED USERS: Health Care Providers & Physicians.” View full resource at touchcardiology.com
Most Recently Shared on August 26, 2009 at 11:25 am By:
Touch Cardiology Cardiology and Health News
Guidelines: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents http://ow.ly/lmJq
Higher co-payments increase chance of early discontinuation of breast cancer therapy
physorg.com — “A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer.” View full resource at physorg.com
Most Recently Shared on December 11, 2010 at 11:13 pm By:
Higher co-payments increase chance of early discontinuation of breast cancer therapy http://bit.ly/id7mjb
Higher co-pays increase possibility of early discontinuation, inadequate use of breast cancer therapy - - Drug Topics
drugtopics.modernmedicine.com — “A higher prescription co-payment, especially among older women, is associated with the early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone-sensitive, early-stage breast cancer, research shows.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on December 30, 2010 at 5:50 am By:
Drugs and Devices OW OW Health
Higher co-pays increase possibility of early discontinuation, inadequate use of breast cancer therapy:... http://bit.ly/hquMYT #drug
Higher co-payments lead women to discontinue life-saving breast cancer therapy - JSOnline
jsonline.com — “Higher co-payments lead women to discontinue life-saving breast cancer therapy - JSOnline” View full resource at jsonline.com
Most Recently Shared on December 14, 2010 at 5:36 pm By:
Men For A Cause (TM) Health Organization
Higher co-payments lead women to discontinue life-saving breast cancer therapy http://ping.fm/FF1l2
Higher co-pays increase possibility of early discontinuation, inadequate use of breast cancer therapy - - ModernMedicine
modernmedicine.com — “A higher prescription co-payment, especially among older women, is associated with the early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone-sensitive, early-stage breast cancer, research shows.” View full resource at modernmedicine.com
Most Recently Shared on December 30, 2010 at 11:37 pm By:
Men For A Cause (TM) Health Organization
Higher co-pays increase possibility of early discontinuation, inadequate use of breast cancer therapy http://ping.fm/VkJ7H
Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report
news-medical.net — “According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months” View full resource at news-medical.net
Most Recently Shared on June 14, 2010 at 1:12 pm By:
Osteoporosis News: Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months:... http://bit.ly/aUwQpN
Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC
news-medical.net — “Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).” View full resource at news-medical.net
Most Recently Shared on March 12, 2010 at 1:41 pm By:
Lung Cancer News: Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced... http://bit.ly/a3oRUV
Increased incidence of hip fracture reported after HT discontinuation
endocrinetoday.com — “NAMS Annual Meeting CHICAGO " Women who abruptly discontinue postmenopausal hormone therapy appear to be at significantly short-term incre” View full resource at endocrinetoday.com
Most Recently Shared on October 11, 2010 at 3:15 pm By:
Increased incidence of hip fracture reported after hormone therapy discontinuation http://ow.ly/2RGiT #NAMS #menopause #osteoporosis
APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued - Drugs.com MedNews
drugs.com — “Nov 18, 2010 - Bristol-Myers Squibb Company (NYSE BMY) and Pfizer (NYSE PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical” View full resource at drugs.com
Most Recently Shared on November 19, 2010 at 3:08 pm By:
Drugs and Devices OW OW Health
APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued: PRINCETON... http://bit.ly/94rWRc #drug
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
-
Dr. Steven Goldy
Cosmetic and General Dentistry, I am very passionate about helping people improve their smile and dental health. For special promotions - http://bit.ly/15sxor
-
MNT Women's Health
The latest women's health and gynecology news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
